TrialScience translational medicine2022

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.

Robert J Benschop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.